Captech Santé
VC Fund
Les Hauts-saint-jean, France
Captech Santé is a VC fund in Les Hauts-saint-jean focused on Health Care and Biotechnology. CAPTECH Santé Nutrition fund invests in biotechnology, health, and nutrition projects, managed by experts in life sciences and supported by FINORPA Gestion.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries Captech Santé invests in
Stages Captech Santé invests in
Countries Captech Santé invests in
Investment Focus
Industry
- Health Care 4 (40%)
- Biotechnology 4 (40%)
- Medical 2 (20%)
- Pharmaceutical 2 (20%)
- Delivery 1 (10%)
Stage
- Series A 4 (40%)
- Venture - Series Unknown 3 (30%)
- Seed 2 (20%)
- Series B 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Bon Vivant
|
A French biotechnology startup founded by Hélène Briand, and Stéphane Mac Millan that leverages precision fermentation technology to develop plant-based milk using yeast to create non-dairy alternatives that are similar in texture and taste to its counterparts. | $29.4M / Series A / Feb 24, 2026 | |
Lattice Medical
|
Today 1 women on 8 has a breast cancer, 40% of them will have a mastectomy to cure cancer and only 14% of them will have reconstruction because actual technics does no fit for breast reconstruction. That’s why LATTICE MEDICAL develops the implantable device MATTISSE which answer to clinical and societal issues and allow women to get back theirbodies and life. MATTISSE implant allows a natural reconstruction by regenerating autologous adipose tissues, custom reconstruction thanks to 3D printing and single surgery due to fully biodegradable material, which fully disappear after reconstruction. We aim in long term to replace silicon-based implant by our technology. | $50M / Series B / Oct 24, 2025 | |
Genoskin
|
Genoskin is a biotech company that leverages its expertise in skin biology and immunology to enhance the development of medications and vaccines. | $5.4M / Series A / Sep 16, 2025 | |
Hemerion
|
Hemerion is focused on creating innovative cancer treatments. The focus is on cutting-edge methods to treat glioblastoma, the most prevalent and dangerous primary brain tumour. | $2.8M / Series A / May 22, 2025 | |
Vetbiolix
|
Développement clinique de solutions thérapeutiques innovantes pour le marché vétérinaire chiens & chats : oncologie & pathologies chroniques | $4.2M / Venture - Series Unknown / Dec 06, 2024 | |
Vaxinano
|
Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder. | $6.5M / Venture - Series Unknown / Oct 29, 2024 | |
|
Vetbiolix
|
Développement clinique de solutions thérapeutiques innovantes pour le marché vétérinaire chiens & chats : oncologie & pathologies chroniques | $2.8M / Seed / Sep 08, 2024 | |
Nutriearth
|
Nutriearth is a biotech firm that develops nutritional ingredients for human and animal health. | $8.6M / Venture - Series Unknown / Jul 01, 2024 | |
|
Bon Vivant
|
A French biotechnology startup founded by Hélène Briand, and Stéphane Mac Millan that leverages precision fermentation technology to develop plant-based milk using yeast to create non-dairy alternatives that are similar in texture and taste to its counterparts. | $15.9M / Seed / Oct 11, 2023 | |
|
Lattice Medical
|
Today 1 women on 8 has a breast cancer, 40% of them will have a mastectomy to cure cancer and only 14% of them will have reconstruction because actual technics does no fit for breast reconstruction. That’s why LATTICE MEDICAL develops the implantable device MATTISSE which answer to clinical and societal issues and allow women to get back theirbodies and life. MATTISSE implant allows a natural reconstruction by regenerating autologous adipose tissues, custom reconstruction thanks to 3D printing and single surgery due to fully biodegradable material, which fully disappear after reconstruction. We aim in long term to replace silicon-based implant by our technology. | $7.8M / Series A / Oct 01, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Captech Santé invest in?
Captech Santé invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Venture - Series Unknown stage. Most of the 10 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Captech Santé last invest?
The most recent investment recorded for Captech Santé closed in Feb 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
